An issue of Endo International plc – (NASDAQ:ENDP) (TSE:ENL) bonds fell 1.5% against their face value during trading on Thursday. The debt issue has a 5.75% coupon and is set to mature on January 15, 2022. The debt is now trading at $85.50 and was trading at $86.94 one week ago. Price moves in a company’s bonds in credit markets sometimes predict parallel moves in its stock price.
Several brokerages have commented on ENDP. ValuEngine upgraded shares of Endo International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Goldman Sachs Group began coverage on shares of Endo International in a research note on Thursday, September 28th. They set a “sell” rating and a $7.00 price objective for the company. Zacks Investment Research cut shares of Endo International from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Piper Jaffray Companies restated a “hold” rating and set a $9.00 price objective on shares of Endo International in a research note on Sunday, September 17th. Finally, Leerink Swann began coverage on shares of Endo International in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $11.27.
Endo International plc – (NASDAQ:ENDP) traded down $0.15 on Thursday, hitting $7.92. 7,473,130 shares of the company traded hands, compared to its average volume of 4,840,000. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. Endo International plc – has a 1 year low of $5.77 and a 1 year high of $15.47. The firm has a market cap of $1,800.00, a PE ratio of -0.41, a P/E/G ratio of 2.98 and a beta of 0.59.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The firm had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. During the same period in the previous year, the business posted $1.01 EPS. The business’s revenue was down 11.0% compared to the same quarter last year. analysts forecast that Endo International plc – will post 3.67 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of ENDP. Schroder Investment Management Group acquired a new position in shares of Endo International in the 2nd quarter valued at $330,000. Systematic Financial Management LP lifted its stake in shares of Endo International by 14.6% in the 2nd quarter. Systematic Financial Management LP now owns 149,485 shares of the company’s stock valued at $1,670,000 after purchasing an additional 19,065 shares during the period. Riverhead Capital Management LLC lifted its stake in shares of Endo International by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after purchasing an additional 5,887 shares during the period. Teachers Advisors LLC lifted its stake in shares of Endo International by 1.9% in the 2nd quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after purchasing an additional 15,928 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of Endo International by 1.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after purchasing an additional 10,387 shares during the period. Hedge funds and other institutional investors own 93.06% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/12/endo-international-endp-bond-prices-fall-1-5.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.